We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: Salesforce, Intuit, Bristol-Myers Squibb, QUALCOMM and Lockheed Martin
Read MoreHide Full Article
For Immediate Release
Chicago, IL – December 29, 2021 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: salesforce.com, inc. (CRM - Free Report) , Intuit Inc. (INTU - Free Report) , Bristol-Myers Squibb Company (BMY - Free Report) , QUALCOMM Incorporated (QCOM - Free Report) and Lockheed Martin Corporation (LMT - Free Report) .
Here are highlights from Tuesday’s Analyst Blog:
Top Research Reports for salesforce, Intuit and Bristol-Myers Squibb
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Salesforce, Intuit, and Bristol-Myers Squibb. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Shares of salesforce have underperformed the Zacks Computer Software industry over the past year (+16.1% vs. +41.9%), however, things seem to be improving for it. The Zacks analyst believes that salesforce has been benefiting from a robust demand environment on the back of the ongoing digital transformation.
The rapid adoption of its cloud-based solutions has also been driving demand for its products. CRM’s sustained focus on introducing more products aligned with customer needs is another positive. The recent acquisition of Slack is likely to position CRM as a leader in enterprise team collaboration solution space. Stiff competition and unfavorable currency fluctuations, however, remain as major concerns for salesforce.
Intuit shares have gained +72.7% in the year to date period against the Zacks Computer Software industry’s gain of +42.3%. The Zacks analyst believes that Intuit has been benefiting from strong momentum in online ecosystem revenues as well as professional tax revenues.
The TurboTax Live offering is also driving growth in the Consumer tax business. INTU’s strategy of shifting its business to cloud-based subscription model is likely to generate stable revenues in the long run. Pandemic related global lockdowns, higher expenses due to increased investments in marketing and engineering teams are some of the major concerns though.
Shares of Bristol-Myers have gained +3.6% in the last three months against the Zacks Biomedical and Genetics industry’s loss of -14.4%. The Zacks analyst believes that strong sales of drugs like Opdivo, Revlimid and Eliquis are likely to continue driving BMY’s top line. Bristol-Myers’ efforts to develop its pipeline are also encouraging.
The label expansion of Opdivo into indications of lung cancer, renal cancer and gastric cancer has been boosting sales. The approval of new drugs like Reblozyl will add a new stream of revenues, which should also boost growth. Generic competition as well as pipeline setbacks, however, remain as major threats.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: Salesforce, Intuit, Bristol-Myers Squibb, QUALCOMM and Lockheed Martin
For Immediate Release
Chicago, IL – December 29, 2021 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: salesforce.com, inc. (CRM - Free Report) , Intuit Inc. (INTU - Free Report) , Bristol-Myers Squibb Company (BMY - Free Report) , QUALCOMM Incorporated (QCOM - Free Report) and Lockheed Martin Corporation (LMT - Free Report) .
Here are highlights from Tuesday’s Analyst Blog:
Top Research Reports for salesforce, Intuit and Bristol-Myers Squibb
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Salesforce, Intuit, and Bristol-Myers Squibb. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Shares of salesforce have underperformed the Zacks Computer Software industry over the past year (+16.1% vs. +41.9%), however, things seem to be improving for it. The Zacks analyst believes that salesforce has been benefiting from a robust demand environment on the back of the ongoing digital transformation.
The rapid adoption of its cloud-based solutions has also been driving demand for its products. CRM’s sustained focus on introducing more products aligned with customer needs is another positive. The recent acquisition of Slack is likely to position CRM as a leader in enterprise team collaboration solution space. Stiff competition and unfavorable currency fluctuations, however, remain as major concerns for salesforce.
(You can read the full research report on salesforce here >>>)
Intuit shares have gained +72.7% in the year to date period against the Zacks Computer Software industry’s gain of +42.3%. The Zacks analyst believes that Intuit has been benefiting from strong momentum in online ecosystem revenues as well as professional tax revenues.
The TurboTax Live offering is also driving growth in the Consumer tax business. INTU’s strategy of shifting its business to cloud-based subscription model is likely to generate stable revenues in the long run. Pandemic related global lockdowns, higher expenses due to increased investments in marketing and engineering teams are some of the major concerns though.
(You can read the full research report on Intuit here >>>)
Shares of Bristol-Myers have gained +3.6% in the last three months against the Zacks Biomedical and Genetics industry’s loss of -14.4%. The Zacks analyst believes that strong sales of drugs like Opdivo, Revlimid and Eliquis are likely to continue driving BMY’s top line. Bristol-Myers’ efforts to develop its pipeline are also encouraging.
The label expansion of Opdivo into indications of lung cancer, renal cancer and gastric cancer has been boosting sales. The approval of new drugs like Reblozyl will add a new stream of revenues, which should also boost growth. Generic competition as well as pipeline setbacks, however, remain as major threats.
(You can read the full research report on Bristol-Myers here >>>)
Other noteworthy reports we are featuring today include Qualcomm and Lockheed Martin.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.